Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-04-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-3360PMID 24727329PMCID PMC4104657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection

  2014cited by this paper
• PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma

  2013cited by this paper
• Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

  2013cited by this paper
• Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma

  2013influential reference
• The HPV16 E6 Oncoprotein Causes Prolonged Receptor Protein Tyrosine Kinase Signaling and Enhances Internalization of Phosphorylated Receptor Species

  2013cited by this paper
• Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2012cited by this paper
• Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials

  2012cited by this paper
• First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

  2012cited by this paper
• First-inHuman Trial of a STAT 3 Decoy Oligonucleotide in Head and Neck Tumors : Implications for Cancer Therapy

  2012cited by this paper
• Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

  2012cited by this paper
• Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

  2012cited by this paper
• c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

  2012cited by this paper
• The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

  2011cited by this paper
• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

  2011cited by this paper
• Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

  2011cited by this paper
• Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.

  2011cited by this paper
• Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

  2011cited by this paper
• Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue.

  2011cited by this paper
• Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

  2010cited by this paper
• Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma

  2010cited by this paper
• Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer

  2010cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Kinin B2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas

  2008cited by this paper
• Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report

  2008cited by this paper
• Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry

  2007cited by this paper
• Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative

  2007cited by this paper
• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  2007cited by this paper
• Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.

  2006influential reference
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands.

  2005cited by this paper
• Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2005influential reference
• Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck

  2004influential reference
• Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells

  2004cited by this paper
• A model for random sampling and estimation of relative protein abundance in shotgun proteomics.

  2004cited by this paper
• Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: Comparison with clinical and radiologic examinations

  2003cited by this paper
• Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

  2003cited by this paper
• TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells

  2003cited by this paper
• Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck*

  2003cited by this paper
• Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.

  2002cited by this paper
• STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.

  2002cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• Prognostic significance of proliferative and apoptotic markers in oral tongue squamous cell carcinomas.

  1999cited by this paper
• Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

  1998cited by this paper
• Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

  1998cited by this paper
• Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

  1991cited by this paper
• More powerful procedures for multiple significance testing.

  1990cited by this paper

• Exploring the role of extracellular vesicles in otorhinolaryngology: From diagnostics to therapeutic potential.

  2026cites this paper
• Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets.

  2025cites this paper
• Cancer-associated fibroblasts derived amphiregulin promotes HNSCC progression and drug resistance of EGFR inhibitor.

  2025cites this paper
• Mononuclear phagocyte system-related multi-omics features yield head and neck squamous cell carcinoma subtypes with distinct overall survival, drug, and immunotherapy responses

  2024cites this paper
• Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells

  2024cites this paper
• Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction.

  2024cites this paper
• Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma

  2023influential citation
• Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

  2023cites this paper
• Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit.

  2023cites this paper
• Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status

  2022cites this paper
• A dataset resource for clinically associated phosphosites in hepatocellular carcinoma

  2022cites this paper
• Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma.

  2022cites this paper
• NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models

  2022cites this paper
• Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy?

  2021cites this paper
• NSAIDs: Old Acquaintance in the Pipeline for Cancer Treatment and Prevention─Structural Modulation, Mechanisms of Action, and Bright Future.

  2021cites this paper
• Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC

  2020cites this paper
• c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?

  2020cites this paper
• Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma

  2020cites this paper
• Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

  2020cites this paper
• Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma

  2020cites this paper
• Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients

  2019cites this paper
• Window of opportunity trials in head and neck cancer

  2019influential citation
• Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?

  2019cites this paper
• Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

  2019cites this paper
• The role of 1,25(oh)2d3 and its analogs in proliferation and differentiation of squamous cell carcinoma of the head and neck – literature review

  2019cites this paper
• Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits

  2018cites this paper
• Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma

  2018influential citation
• Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.

  2018cites this paper
• Chapter 7 – Erlotinib

  2017cites this paper
• Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck

  2017cites this paper
• Envoi—An Appraisal of Targeted Therapies for Head and Neck Cancer

  2017cites this paper
• Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

  2017cites this paper
• Trends in Surgical Research in Head and Neck Cancer

  2017cites this paper
• Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab

  2016cites this paper
• Squamous Cell Cancers: A Unified Perspective on Biology and Genetics.

  2016cites this paper
• Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

  2016cites this paper
• Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program

  2016cites this paper
• Window of opportunity studies: Do they fulfil our expectations?

  2016influential citation
• Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions.

  2015cites this paper
• Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

  2015influential citation
• Recent Advance in Drug Development of Squamous Cell Carcinoma.

  2015cites this paper
• Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

  2015cites this paper
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

  2015cites this paper
• Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness

  2015cites this paper
• Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer

  2015cites this paper
• Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor

  2014cites this paper
• Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer

  2014cites this paper
• Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation

  2014cites this paper
• The phosphatidyl-inositol 3-kinase/Akt/mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer

  2014cites this paper